While the CDC and FDA continue their review of six reported cases of a “rare and severe type of blood clot” after receiving the Johnson & Johnson vaccine, the two organizations recommend halting the use of the J&J vaccine until after they meet with the Advisory Committee on Immunization Practices and review further data on Wednesday.. As of earlier today, the U.S. has administered more than 6.8 million J&J vaccines.
“Treatment of this specific type of blood clot is different from the treatment that might typically be administered,” according to the joint CDC and FDA statement. ”Usually, an anticoagulant drug called heparin is used to treat blood clots. In this setting, administration of heparin may be dangerous, and alternative treatments need to be given.”
The CDC is set to meet with the Advisory Committee on Immunization Practices on Wednesday to review these six cases and assess potential significance.
The cases occurred among women between 18 and 48 years old. Symptoms were noticeable within 6 to 13 days after receiving the vaccine.
“Right now, these adverse events appear to be extremely rare,” according to the joint statement. “COVID-19 vaccine safety is a top priority for the federal government, and we take all reports of health problems following COVID-19 vaccination very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider.”
For health care providers, click here to report any adverse events to the Vaccine Adverse Event Reporting System. As of earlier today, more than 6.8 million doses of the J&J vaccine have been administered within the U.S.